Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

Historic Construction in Progress for SAB Biotherapeutics (SABS) over the last 3 years, with Q1 2023 value amounting to $329617.0.

  • SAB Biotherapeutics' Construction in Progress changed N/A to $329617.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $329617.0, marking a year-over-year change of. This contributed to the annual value of $308317.0 for FY2022, which is 9331.02% down from last year.
  • According to the latest figures from Q1 2023, SAB Biotherapeutics' Construction in Progress is $329617.0.
  • SAB Biotherapeutics' Construction in Progress' 5-year high stood at $4.6 million during Q4 2021, with a 5-year trough of $308317.0 in Q4 2022.
  • Over the past 3 years, SAB Biotherapeutics' median Construction in Progress value was $329617.0 (recorded in 2023), while the average stood at $1.7 million.
  • Over the last 5 years, SAB Biotherapeutics' Construction in Progress had its largest YoY gain of 9331.02% in 2022, and its largest YoY loss of 9331.02% in 2022.
  • Quarter analysis of 3 years shows SAB Biotherapeutics' Construction in Progress stood at $4.6 million in 2021, then tumbled by 93.31% to $308317.0 in 2022, then increased by 6.91% to $329617.0 in 2023.
  • Its Construction in Progress was $329617.0 in Q1 2023, compared to $308317.0 in Q4 2022 and $4.6 million in Q4 2021.